Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMA 006

Next Previous
X
Search
Drug Profile

AMA 006

Alternative Names: AMA-006

Latest Information Update: 22 Nov 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amarna Therapeutics
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Factor VIII replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 13 Oct 2022 AMA 006 is available for licensing as of 12 Oct 2022. https://www.amarnatherapeutics.com/partners.html
  • 12 Oct 2022 Amarna Therapeutics has patent protection for Method for the production of recombinant polyomaviral vector particles in Canada, Japan, Spain, Australia, China, Germany, France, and USA, prior to October 2022
  • 12 Oct 2022 Amarna Therapeutics has patents pending for Method for the production of recombinant polyomaviral vector particles in Denmark, South Korea and Mexico

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top